A Multi-center, phase 1/2 open label study of Selinexor (KPT-330), Lenalidomide, and Dexamethasone in patients with R/R MM

Administered By

Duke Cancer Institute

Awarded By

Karyopharm Therapeutics

Contributors

Gasparetto, Cristina Principal Investigator

Start/End

July 15, 2015 - September 13, 2017